Treatment with the IRS1 inhibitor NT157 (ref. 47) reduced proliferation in MM cell lines, highlighting IRS1 as a potential selective target for therapy (Extended Data Fig. 9d). This evidence concerns the gene IRS1 and Miyoshi myopathy.